Agilent Technologies, Inc. $A Stock Position Decreased by Birmingham Capital Management Co. Inc. AL

Birmingham Capital Management Co. Inc. AL trimmed its stake in Agilent Technologies, Inc. (NYSE:A) by 15.1% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,250 shares of the medical research company’s stock after selling 580 shares during the period. Birmingham Capital Management Co. Inc. AL’s holdings in Agilent Technologies were worth $380,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the stock. Generation Investment Management LLP increased its position in Agilent Technologies by 19.8% in the 1st quarter. Generation Investment Management LLP now owns 4,983,556 shares of the medical research company’s stock worth $582,976,000 after buying an additional 824,243 shares during the period. GAMMA Investing LLC increased its position in Agilent Technologies by 15,648.1% in the 1st quarter. GAMMA Investing LLC now owns 627,247 shares of the medical research company’s stock worth $73,375,000 after buying an additional 623,264 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Agilent Technologies by 18.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,836,105 shares of the medical research company’s stock worth $448,748,000 after buying an additional 604,124 shares during the period. Two Sigma Investments LP increased its position in Agilent Technologies by 345.9% in the 4th quarter. Two Sigma Investments LP now owns 769,897 shares of the medical research company’s stock worth $103,428,000 after buying an additional 597,249 shares during the period. Finally, Mackenzie Financial Corp lifted its stake in shares of Agilent Technologies by 141.5% in the first quarter. Mackenzie Financial Corp now owns 935,893 shares of the medical research company’s stock valued at $109,481,000 after buying an additional 548,344 shares during the period.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the sale, the chief executive officer owned 37,448 shares of the company’s stock, valued at $4,397,893.12. This represents a 3.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Agilent Technologies Price Performance

Shares of A stock opened at $124.24 on Thursday. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $153.84. The firm has a market cap of $35.22 billion, a price-to-earnings ratio of 29.16, a P/E/G ratio of 3.93 and a beta of 1.24. The stock’s fifty day simple moving average is $119.61 and its 200 day simple moving average is $116.13. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.71.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.37. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. During the same period last year, the firm posted $1.32 EPS. The firm’s quarterly revenue was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. On average, analysts expect that Agilent Technologies, Inc. will post 5.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. TD Cowen increased their target price on shares of Agilent Technologies to $150.00 and gave the company a “buy” rating in a research note on Thursday, May 29th. Wells Fargo & Company increased their target price on shares of Agilent Technologies from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, August 28th. UBS Group reduced their target price on shares of Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating for the company in a research note on Thursday, May 29th. JPMorgan Chase & Co. reduced their target price on shares of Agilent Technologies from $160.00 to $155.00 and set an “overweight” rating for the company in a research note on Thursday, May 29th. Finally, Barclays reiterated an “equal weight” rating and issued a $125.00 target price on shares of Agilent Technologies in a research note on Friday, August 29th. Six analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $139.25.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.